Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Rapid, profound and durable antiviral effects in treatment-naïve or currently-not-treated subjects with chronic hepatitis B virus infection that received 300 mg pevifoscorvir sodium monotherapy for 96 weeks

Tuesday, December 9, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The study reports significant antiviral effects from 300 mg pevifoscorvir sodium monotherapy in treatment-naïve or currently untreated patients with chronic hepatitis B virus infection. The treatment demonstrated rapid and durable results over a 96-week period, indicating its potential as a viable therapeutic option for this patient population.
Price reaction · baseline $11.03 (2025-12-09T19:38:00.000Z) · hit during market hours · 2 other ALGS headline(s) in the window, move may be shared
day 0 close · peak
+0.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Demonstrated rapid antiviral effects in chronic HBV patients.
  • Treatment showed durability over a 96-week period.
  • Monotherapy with pevifoscorvir sodium is promising for treatment-naïve subjects.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is pevifoscorvir sodium?

Pevifoscorvir sodium is an antiviral medication used to treat chronic hepatitis B virus infection.

How long was the treatment duration in the study?

The treatment duration was 96 weeks.

Who were the subjects in the study?

The subjects included treatment-naïve or currently untreated patients with chronic HBV infection.

What were the results of the treatment?

The treatment showed rapid and durable antiviral effects in the patients.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare chronic hepatitis B HBV treatment pevifoscorvir antiviral therapy
Last updated: Dec 9, 2025

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →